TransCode Therapeutics, Inc. is a Boston-based biotech company focusing on RNA-based therapies utilizing advanced nanotechnology, with a Nasdaq ticker of RAZ.

# Company Summary: TransCode Therapeutics, Inc.

**Overview:**
TransCode Therapeutics, Inc. is a biotechnology company based in Boston, Massachusetts, incorporated in Delaware. The company focuses on developing innovative therapies, likely in the oncology or related medical fields, utilizing advanced nanotechnology and RNA-based approaches, as indicated by the expertise of its scientific co-founders and board members.

**Key Details:**
- **Stock Ticker:** RNAZ (traded on Nasdaq)
- **Principal Offices:** 6 Liberty Square, #2382, Boston, MA 02109
- **Telephone:** (857) 837-3099
- **Incorporation:** Delaware, IRS Employer ID: 81-1065054

**Management and Leadership:**
- **Interim CEO & CFO:** Thomas A. Fitzgerald, aged 74
- **Board Members:** Philippe P. Calais, Erik Manting, Magda Marquet
- **Scientific Leadership:** Zdravka Medarova, PhD (Chief Scientific Officer), Anna Moore, PhD (Scientific Advisor)

**Employees and Significant Employees:**
- The company is relatively small with only a few key personnel:
  - Thomas A. Fitzgerald (Executive Officer)
  - Zdravka Medarova, PhD (Chief Scientific Officer, employee since October 2021)
  - Anna Moore, PhD (Scientific Advisor since 2016)

**Customers and Revenue:**
- The provided documentation does not specify the number of customers.
- No revenue or income figures are disclosed in the provided extract.

**Financials:**
- As of June 30, 2024, the company's market value was approximately $7.3 million based on stock closing prices.
- **Outstanding Shares:** 23,341,336 shares as of April 28, 2025.
- **Annual Revenue & Income:** Not disclosed in the provided documentation.

**Business Focus:**
- The company's development efforts include innovative RNA-based therapeutics, likely involving nanoparticle delivery systems, gene regulation, or similar biotechnology approaches.
- The Board and management have extensive experience in biotech and pharmaceutical industries, with expertise in corporate finance, drug development, and biotech management.

**Corporate Governance:**
- The company maintains committees for audit, compensation, and governance.
- It adheres to Nasdaq rules concerning director independence and operates under established policies for related-party transactions and insider trading.

**Additional Information:**
- The company is classified as a smaller reporting company and an emerging growth company.
- The company has no major legal proceedings or restatements affecting financial statements disclosed in the SEC filings.

**Note:**
- The provided documentation focuses on governance, management, and legal disclosures. It does not include specific operational metrics such as customer count, revenue, net income, or detailed financial performance.

TransCode Therapeutics, Inc. is an RNA oncology company focused on developing RNA-based therapeutics to target and combat metastatic cancer through its proprietary TTX delivery platform.

## Company Overview: TransCode Therapeutics, Inc.

**Business Focus:**  
TransCode Therapeutics, Inc. is an RNA oncology company dedicated to developing RNA-based therapeutics aimed at defeating cancer. The company's innovative approach involves the intelligent design and effective delivery of RNA therapeutics through its proprietary **TTX delivery platform**. This platform is designed to overcome significant challenges of RNA delivery to tumors and metastatic sites that have traditionally proven difficult, aiming to target previously undruggable genetic elements associated with cancer.

### Key Aspects of the Business:

- **Product Development:**  
  - **Lead Candidate:** TTX-MC138 targets microRNA-10b (miR-10b), a key regulator of metastatic disease in multiple cancer types, including breast, pancreatic, and glioblastomas.
  - **Current Development Stage:**  
    - Initiated a Phase 0 clinical trial (First-in-Human trial) with TTX-MC138 in August 2023.
    - Planning a Phase I/II clinical trial with TTX-MC138, pending FDA review expected by Q2 2024.
  
- **Technology Platform:**  
  - The **TTX platform** utilizes iron oxide nanoparticles for the delivery of synthetic oligonucleotides, optimizing the targeting and accumulation of RNA therapeutics in tumor cells.
  - The platform is modular, allowing for customization in the development of RNA therapeutics tailored to specific cancer targets.

### Operations:

- **Collaborations:**  
  - Entered a strategic collaboration agreement with The University of Texas M. D. Anderson Cancer Center in July 2022 to support preclinical and clinical trial activities, with a financial commitment of up to $10 million over five years.
  
- **Pipeline Programs:**  
  - Other preclinical programs include TTX-siPDL1 (targeting PD-L1), TTX-RIGA (activating innate immunity), and TTX-CRISPR (gene editing for cancer therapies). The pipeline also explores mRNA-based cancer vaccines.

### Financials:

- **Number of Employees:**  
  As of March 20, 2024, the company had **10 employees**, including three with Ph.D. degrees.
  
- **Revenue:**  
  Currently, **TransCode has not generated any revenue** as the product candidates are still in early stages of development and undergoing clinical trials.

- **Net Loss and Financial Position:**  
  - For the fiscal year ending December 31, 2023, the company reported a **net loss of approximately $18.5 million**.
  - As of December 31, 2023, the company had cash reserves totaling **approximately $2.8 million** and anticipates needing additional funding to support ongoing clinical trials and operational costs.

### Market Potential:
TransCode is positioned within a significant market, as the global metastatic cancer treatment market was estimated at **$63.03 billion in 2019**, expected to reach **$111.16 billion by 2027**, growing at a compound annual growth rate (CAGR) of **7.3%**. This growth is driven by the rising prevalence of cancer and high unmet medical needs of patients suffering from metastatic disease.

### Summary:
TransCode Therapeutics is at the forefront of RNA oncology, leveraging its proprietary TTX platform to develop innovative therapies against metastatic cancers. With a small, experienced team and an ambitious pipeline, the company aims to overcome traditional delivery hurdles associated with RNA therapeutics, making significant strides in potentially transforming the landscape of cancer treatment. However, without current revenue and ongoing financial losses, securing additional funding will be critical for its future operations and success.

Transcode Therapeutics, Inc.

10-K / April 30, 2025

10-K / April 1, 2024

10-K / April 30, 2025

Company Summary: TransCode Therapeutics, Inc.